Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma
Status:
Withdrawn
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. LMB-2 immunotoxin can find cancer cells and kill them without harming
normal cells. Giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin may kill
more cancer cells.
PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide
followed by LMB-2 immunotoxin works in treating patients with Hodgkin's lymphoma.
Phase:
N/A
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)